Prevest Denpro Ltd Q2 FY2024 Concall Summary

Key Takeaways

• Resilient H1 despite export headwinds: Revenue grew 12% YoY to INR28 crores and PAT rose 10% to INR7.72 crores, even as foreign exchange crises in Africa and South America choked off orders from previously promising markets.
• Domestic engine firing at 30%: A 30% domestic growth rate, driven by dealer expansion and a strengthened marketing team, more than offset the export stall and kept the top line moving.
• Margin compression is deliberate, not structural: EBITDA margin slipped from 40.9% to 38.4%, a 1-2% dip management attributes to a mix shift toward lower-margin domestic sales and upfront investment in R&D and sales headcount ahead of new product launches.
• New product pipeline is now real: Oral care products are days from commercial launch, 3D dental resins are already marketing, and white labelling for two US companies has begun generating revenue, setting up multiple growth vectors for H2.
• What to watch next quarter: Whether the oral care commercial launch converts sampling excitement into revenue, any resolution in the African and South American forex crises, and if the 1-2% margin dip is recovered as promised.

Export Slowdown & the Domestic Offset

• Forex crises froze key markets: Orders from Argentina, Egypt and Sudan collapsed because those countries cannot access foreign exchange to pay for imports. These were promising markets, and management cannot predict when the situation normalizes, though it expects business to bounce back when it does.
• Compensating growth elsewhere: The company maintained nearly flat export revenue year-over-year by growing in North America, Europe and Eastern countries, absorbing the shock without a net decline in the export book.
• Domestic surge filled the gap: A 30% domestic growth rate in H1, powered by a marketing team under Vaibhav Munjal and penetration into every corner of the country, turned the domestic market into the primary growth driver.
• Dealer network expanding: The dealer count grew from roughly 145-150 to 155-160, with five new dealers added this year. Debtor days stretched to 60 as the company extended capital support to new distributors, a trade norm management considers secured and sales-boosting.
• Dentist adoption friction exists but is manageable: Dentists hesitate to shift to new products, yet 30% domestic growth demonstrates acceptance. Management acknowledges the preference inertia but points to the growth rate as proof the products are gaining traction.

Atul Modi: "There is a slowdown in export market because, as I have already explained, that there is no foreign exchange crisis in many African countries and also in South American countries. So we are facing challenges from these countries."

New Product Launches: Oral Care & 3D Resins

• Oradox oral care range imminent: All regulatory compliances are complete and manufacturing licenses are expected within days. A sampling exercise with dentists and trade partners generated what management calls amazing excitement, and the formal launch will happen at upcoming trade shows in H2.
• 3D dental resins already in market: Marketing has begun and the company reports an encouraging response from across the country, positioning it in the emerging digital dentistry segment.
• Capacity utilization plan is explicit: Management expects to use about 10% of capacity for the new product line in the remaining six months of FY24, then grow that by at least 10% every year to reach 60-70% utilization within five years. No major capex is needed for 4-5 years given current 40% utilization.
• Margin expectations are consistent: The oral hygiene products are premium and value-added, and management expects the same kind of profit margins, around 40% EBITDA, as the existing portfolio.
• Revenue guidance withheld: Management says it is too early to give a top-line expectation for the oral care segment since commercial launch has not yet happened, though it calls the opportunity huge.

Atul Modi: "So, we are expecting that every year, we should increase our business of the new product line by at least 10%. So that in the next five years, we reach to capacity utilization of 60% to 70%."

White Labelling & International Expansion

• US white labelling is live and revenue-generating: The company has begun private labelling for two American companies, and management describes the relationship and cooperation as very successful, calling this just the beginning.
• Australia registration secured: The company acquired registration with Australian federal authorities, opening doors to ASEAN markets. Most products are approved by the Australian Government Health Organization, and sampling at a Sydney conference generated positive feedback from distributors keen to partner.
• Cooperation model under negotiation: Pricing and cooperation terms with Australian distributors are still being worked out. Once finalized, business activities will begin, but management does not expect big revenue from Australia in the first year.
• Denvisio Biomed subsidiary incorporated: The new subsidiary will focus on marketing all Prevest DenPro products and will also explore trading opportunities in profitable product lines.

Atul Modi: "This will grow. So this is just the beginning. So we are doing private labelling for two companies in the United States. And we are, our relationship and our cooperation is very successful."

Margins: The 1-2% Dip Explained

• Mix shift is the core driver: The 1-2% EBITDA margin decline, from 40.9% to 38.4%, is substantially due to slower export growth and a higher share of domestic revenue, which carries lower profitability.
• Investment costs added pressure: Employee benefit costs rose as the company hired ahead of commercial production for the new oral care line, including R&D personnel, so that no shortage exists when production scales. USFDA license fees increased to INR34 lakhs, and exhibition and travel expenses also rose.
• Recovery is promised within six months: Management states the 1-2% decline is not significant over a half-year period and believes it can be covered in the next six months, keeping EBITDA in the 38-40% range. Import substitution, price increases, operational expense control, and value-added products are the levers.
• R&D cost reduction is a tailwind: The R&D team successfully developed two raw materials previously imported, reducing production costs and import dependency, which supports margin recovery.

Atul Modi: "So 1% or 2% decrease is not a very significant if you look at the half year figure. So we -- it is possible that we cover up in the next six months. So we will be in this range only 38% to 40%. So we will try to maintain the same level."

R&D, Institutions & the Demand Engine

• R&D facility fully operational: Equipment is running and new products are being developed successfully, including the 3D resin, oral care products and disinfectants.
• Institutional collaborations serve triple duty: The company has tie-ups with about 12 dental institutions in India. These drive innovation through industry-academia exchange, generate revenue from products sold to dental colleges, and introduce students, who are future dentists, to Prevest products.
• Market share ambition is directional, not dated: Management aims to capture roughly 3% of the Indian market share but declined to define any timeline, stating it is not possible in one year or six months, though the company is striving hard to reach that level very soon.
• Inorganic growth on the radar: Management is looking for other business opportunities for diversification and growth, including potential acquisitions.

Sai Kalyan Surapaneni: "Industry, academia, collaborations are very important because it is not just the revenue generated but it is the innovation it can generate. So we exchange ideas. We create new products and then every product we generate has to have a clinical evaluation and clinical feedback from the academia."

Guidance & Commitments

Key Metrics